# Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus

> **NCT00108004** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 400 (estimated)

## Conditions studied

- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** pramlintide acetate

## Key facts

- **NCT ID:** NCT00108004
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2015-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00108004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00108004, "Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00108004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*